Poster: Evaluate Human Specific CD137 Antibodies

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)


Xuesong Huang, Gang Chen*, Lei Zheng, Annie An, Jean-Pierre Wery, Jay Liu*, Xin Dong*, Qian Shi, and Davy Xuesong Ouyang

*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China
CrownBio 2017. Poster. Evaluate Human Specific CD137 Antibodies
Despite the huge clinical success of PD-1/PD-L1 checkpoint inhibitors in multiple tumor types, overall response rate to these agents is still low.

Growing efforts are focusing on priming and activating T cells through agonistic CD137 antibodies as combinatory strategies to improve tumor killing activities of T cells.

Multiple agonistic CD137 antibodies and PD-L1/CD137 bi-specific antibodies are currently under development; however, a lack of preclinical animal models for in vivo efficacy testing of these human-specific therapeutic antibodies has hindered the research process.

Read this Poster to Discover:

  • The creation of a CD137 humanized model for evaluating CD137 mAb therapeutic efficacy

  • That MC38 tumors engrafted in these models respond to anti-CD137 antibody treatment, and combination therapy with CD137 + PD-1/PD-L1 antibodies

  • A range of preclinical target humanized models, including PD-1, CTLA-4, and OX40, used to assess immuno-oncology mAb therapeutic efficacy

Download the Poster Now!

Review the Poster

Your privacy is important to us.
We'll never share your information.